Role Of Cariprazine In Schizophrenia: A Review
Main Article Content
Abstract
Schizophrenia is a severe mental illness and is most commonly observed/ encountered by the majority of clinicians during their clinical practice Among numerous treatment methods, Cariprazine, and its related drugs have shown their clinical efficacy in the treatment of Schizophrenia. Cariprazine is one of the dopamine D3 – preferring the D3/D2 receptor partial agonist, which is indicated for the treatment of individuals suffering from Schizophrenia. It is a partial agonist of the dopamine receptors which has turned out to show efficacious results for the treatment of Schizophrenia, Bipolar Disorder, Mixed and Manic Disorders, and Major Depressive Disorders. This narrative summarises the pharmacological action of the Cariprazine treatment of Schizophrenia.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
Kanchanatawan B, Thika S, Anderson G, Galecki P, Maes M. Affective symptoms in Schizophrenia are strongly associated with neurocognitive deficits indicating disorders in executive functions, visual memory, attention and social cognition. Prog Neuropsychopharmacol Biol Psychiatry. 2018;80[Pt C]:168–76.
Barrowclough C, Haddock G, Wykes W, Beardmore R, Conrod P, et al. 2010. Integrated motivational interviewing and cognitive behavioural therapy for people with psychosis and comorbid substance misuse: randomised controlled trial. Br. Med. J. 341:c6325
Owen MJ, Sawa A, Mortensen PB. Schizophrenia. Lancet. 2016;388[10039]:86–97.
Insel TR. Rethinking Schizophrenia. Nature. 2010;468[7321]:187–93.
Suttajit S, Pilakanta S. Predictors of quality of life among individuals with Schizophrenia. Neuropsychiatr Dis Treat. 2015;11:1371–9
Citrome L. Oral antipsychotic update: a brief review of new and investigational agents for the treatment of Schizophrenia. CNS Spectr. 2012;17[Suppl. 1]:1–9.
Leucht S, Davis JM. Schizophrenia, primary negative symptoms, and soft outcomes in psychiatry. Lancet. 2017;389[10074]:1077–8
Rabinowitz J, Berardo CG, Bugarski-Kirola D, Marder S. Association of prominent positive and prominent negative symptoms and functional health, well-being, healthcare-related quality of life and family burden: a CATIE analysis. Schizophr Res. 2013;150[2–3]:339–42.
Crow, Tim J. "Molecular pathology of Schizophrenia: more than one disease process?." British medical journal 280.6207 [1980]: 66.
Kirkbride, J.B., Errazuriz, A., Croudace, T.J., Morgan, C., Jackson, D., Boydell, J., Murray, R.M. and Jones, P.B., 2012. Incidence of Schizophrenia and other psychoses in England, 1950–2009: a systematic review and meta-analyses. PloS one, 7[3], p.e31660.
Jackson, Don D. "The etiology of Schizophrenia." [1960].
Solmi M, Murru A, Pacchiarotti I, et al. Safety, tolerability, and risks associated with first- and secondgeneration antipsychotics: a state-of-the-art clinical review. Ther Clin Risk Manag. 2017;13:757–77
Bustillo, J.R., Lauriello, J., Horan, W.P. and Keith, S.J., 2001. The psychosocial treatment of Schizophrenia: an update. American Journal of Psychiatry, 158[2], pp.163-175.
Correll CU. From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. Eur Psychiatry. 2010;25[Suppl 2]:S12-2
Kane, J.M. and Correll, C.U., 2010. Past and present progress in the pharmacologic treatment of Schizophrenia. The Journal of clinical psychiatry, 71[9], p.13909.
Davis, J. M., Schaffer, C. B., Killian, G. A., Kinard, C., & Chan, C. [1980]. Important issues in the drug treatment of Schizophrenia. Schizophrenia bulletin, 6[1], 70-87.
Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for Schizophrenia: a meta-analysis. Lancet. 2009;373[9657]:31–41.
Kiss B, Horváth A, Némethy Z, et al. Cariprazine [RGH188], a dopamine D[3] receptor-preferring, D[3]/D[2] dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. J Pharmacol Exp Ther. 2010;333:328–40
Kiss B, Horvath A, Nemethy Z, et al. Cariprazine [RGH-188], a dopamine D3 receptor-preferring, D3/D2 dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. J Pharmacol Exp Ther. 2010;333[1]:328–40
Siever, L. J., & Davis, K. L. [2004]. The pathophysiology of Schizophrenia disorders: perspectives from the spectrum. American Journal of Psychiatry, 161[3], 398-413
Citrome L. Cariprazine in Schizophrenia: clinical efficacy, tolerability, and place in therapy. Adv Ther. 2013;30[2]:114–26
Gyertya´n I, Kiss B, Saghy K, et al. Cariprazine [RGH-188], a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents. Neurochem Int. 2011;59[6]:925–35.
Neill JC, Grayson B, Kiss B, et al. Effects of Cariprazine, a novel antipsychotic, on cognitive deficit and negative symptoms in a rodent model of Schizophrenia symptomatology. Eur Neuropsychopharmacol. 2016;26[1]:3–14.
. Periclou A, Phillips L, Bihorel S, et al. Characterization of population pharmacokinetics of Cariprazine and its major metabolites [abstract no. 104]. In: 169th annual meeting of the American Psychiatric Association. 2016
Jarskog, L.F., Glantz, L.A., Gilmore, J.H. and Lieberman, J.A., 2005. Apoptotic mechanisms in the pathophysiology of Schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 29[5], pp.846-858.
Meisenzahl, E. M., G. J. Schmitt, J. Scheuerecker, and H-J. Möller. "The role of dopamine for the pathophysiology of Schizophrenia." International Review of Psychiatry 19, no. 4 [2007]: 337-345.
Cornblatt, Barbara A., and John G. Keilp. "Impaired attention, genetics, and the pathophysiology of Schizophrenia." Schizophrenia bulletin 20, no. 1 [1994]: 31-46.
Heckers, Stephan, and Christine Konradi. "Hippocampal pathology in Schizophrenia." Behavioral neurobiology of Schizophrenia and its treatment [2010]: 529-553.
Heckers, Stephan. "Neuroimaging studies of the hippocampus in Schizophrenia." Hippocampus 11, no. 5 [2001]: 520-528.
Lodge, Daniel J., and Anthony A. Grace. "Hippocampal dysregulation of dopamine system function and the pathophysiology of Schizophrenia." Trends in pharmacological sciences 32.9 [2011]: 507-513.
Goldman, Morris B., and Colin P. Mitchell. "What is the functional significance of hippocampal pathology in Schizophrenia?." Schizophrenia bulletin 30, no. 2 [2004]: 367-392.
Lodge, D.J. and Grace, A.A., 2011. Developmental pathology, dopamine, stress and Schizophrenia. International Journal of Developmental Neuroscience, 29[3], pp.207-213.
Gomes, F.V., Zhu, X. and Grace, A.A., 2019. Stress during critical periods of development and risk for Schizophrenia. Schizophrenia research, 213, pp.107-113.
Weinberger, DanielR. "Cell biology of the hippocampal formation in Schizophrenia." Biological psychiatry 45.4 [1999]: 395-402.
Meltzer HY. Effect of neuroleptics on the schizophrenic syndrome. Psychopharmacol Ser. 1987;3:255-65. doi: 10.1007/978-3-642-71288-3_30. PMID: 2881291.
Morris BJ, Pratt JA. Novel treatment strategies for Schizophrenia from improved understanding of genetic risk. Clinical genetics. 2014 Nov;86[5]:401-11.
Ereshefsky, Larry. "Treatment strategies for Schizophrenia." Psychiatric Annals 25, no. 5 [1995]: 285-296.
Maroney, M., 2020. An update on current treatment strategies and emerging agents for the management of Schizophrenia. Am J Manag Care, 26[3 Suppl], pp.S55-S61.
Shimomura, Y., Kikuchi, Y., Suzuki, T., Uchida, H., Mimura, M. and Takeuchi, H., 2020. Antipsychotic treatment in the maintenance phase of Schizophrenia: an updated systematic review of the guidelines and algorithms. Schizophrenia Research, 215, pp.8-16.
Nucifora Jr FC, Woznica E, Lee BJ, Cascella N, Sawa A. Treatment resistant Schizophrenia: Clinical, biological, and therapeutic perspectives. Neurobiology of disease. 2019 Nov 1;131:104257.
Bajouco, Miguel, and David Mota. "Cariprazine on Psychosis: Beyond Schizophrenia–A Case Series." Neuropsychiatric Disease and Treatment 18 [2022]: 1351-1362.
Phalguni, A., McCool, R., Wood, H., Sanderson, A., Rydevik, G., Franklin, B. and James, D., 2022. Systematic literature review and network meta-analysis of lurasidone, brexpiprazole and Cariprazine for Schizophrenia. International Clinical Psychopharmacology, 38[1], pp.45-56.
Laszlovszky I, Barabássy Á, Németh G. Cariprazine, a broad-spectrum antipsychotic for the treatment of Schizophrenia: pharmacology, efficacy, and safety. Advances in Therapy. 2021 Jul;38:3652-73.
Barabássy, Á., Sebe, B., Acsai, K., Laszlovszky, I., Szatmári, B., Earley, W.R. and Németh, G., 2021. Safety and tolerability of Cariprazine in patients with Schizophrenia: a pooled analysis of eight phase II/III studies. Neuropsychiatric Disease and Treatment, pp.957-970.
Earley W, Guo H, Daniel D, Nasrallah H, Durgam S, Zhong Y, Patel M, Barabássy Á, Szatmári B, Németh G. Efficacy of Cariprazine on negative symptoms in patients with acute Schizophrenia: a post hoc analysis of pooled data. Schizophrenia research. 2019 Feb 1;204:282-8.
Kiss, Imre, Ágnes Fábián, György Benedek, and Szabolcs Kéri. "When doors of perception open: visual contrast sensitivity in never-medicated, first-episode Schizophrenia." Journal of Abnormal Psychology 119, no. 3 [2010]: 586.
Zlatanova, Hristina Ivanova, Maria Todorova Georgieva-Kotetarova, Natalia Borisova Vilmosh, and Ilin Kostadinov Kandilarov. "Evaluation of the Effect of Cariprazine on Memory and Cognition in Experimental Rodent Models." International Journal of Environmental Research and Public Health 19, no. 22 [2022]: 14748
Corponi, Filippo, Chiara Fabbri, Istvan Bitter, Stuart Montgomery, Eduard Vieta, Siegfried Kasper, Stefano Pallanti, and Alessandro Serretti. "Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, Cariprazine and lumateperone." European Neuropsychopharmacology 29, no. 9 [2019]: 971-985.
Frankel JS, Schwartz TL. Brexpiprazole and Cariprazine: distinguishing two new atypical antipsychotics from the original dopamine stabilizer aripiprazole. Therapeutic advances in psychopharmacology. 2017 Jan;7[1]:29-41.
Phalguni A, McCool R, Wood H, Sanderson A, Rydevik G, Franklin B, James D. Systematic literature review and network meta-analysis of lurasidone, brexpiprazole and Cariprazine for Schizophrenia. International Clinical Psychopharmacology. 2022 Nov 18;38[1]:45-56.
Davis, K. L., Kahn, R. S., Ko, G., & Davidson, M. [1991]. Dopamine in Schizophrenia: a review and reconceptualization. The American journal of psychiatry.
Guillin, Olivier, Anissa Abi‐Dargham, and Marc Laruelle. "Neurobiology of dopamine in Schizophrenia." International review of neurobiology 78 [2007]: 1-39.
Maia, T.V. and Frank, M.J., 2017. An integrative perspective on the role of dopamine in Schizophrenia. Biological psychiatry, 81[1], pp.52-66.
Fagiolini, Andrea, José Ángel Alcalá, Thomas Aubel, Wojciech Bienkiewicz, Mats Magnus Knut Bogren, Joaquim Gago, Giancarlo Cerveri et al. "Treating Schizophrenia with Cariprazine: from clinical research to clinical practice. Real world experiences and recommendations from an International Panel." Annals of General Psychiatry 19, no. 1 [2020]: 1-11.
Misiak, B., Bieńkowski, P. and Samochowiec, J., 2018. Cariprazine-a novel antipsychotic drug and its place in the treatment of Schizophrenia. Psychiatr Pol, 52[6], pp.971-981.
Periclou, Antonia, Luann Phillips, Parviz Ghahramani, Margit Kapás, Timothy Carrothers, and Tatiana Khariton. "Population pharmacokinetics of Cariprazine and its major metabolites." European Journal of Drug Metabolism and Pharmacokinetics 46 [2021]: 53-69.
Periclou, A., Phillips, L., Ghahramani, P., Kapás, M., Carrothers, T. and Khariton, T., 2021. Population pharmacokinetics of Cariprazine and its major metabolites. European Journal of Drug Metabolism and Pharmacokinetics, 46, pp.53-69.
Cutler A, Bose A, Durgam S, et al. Safety and tolerability of Cariprazine in the long-term treatment of Schizophrenia: results from a 48-week extension study. Poster Presentation NR6- 50, American Psychiatric Association 165th Annual Meeting; May 5–9, 2012; Philadelphia, PA
Kiss, Béla, Zsolt Némethy, Károly Fazekas, Dalma Kurkó, István Gyertyán, Katalin Sághy, István Laszlovszky et al. "Preclinical pharmacodynamic and pharmacokinetic characterization of the major metabolites of Cariprazine." Drug Design, Development and Therapy [2019]: 3229-3248.
Campbell, Rebecca H., Michael Diduch, Kristen N. Gardner, and Christopher Thomas. "Review of Cariprazine in management of psychiatric illness." Mental Health Clinician 7, no. 5 [2017]: 221-229.
Citrome, L., 2013. Cariprazine in bipolar disorder: clinical efficacy, tolerability, and place in therapy. Advances in therapy, 30, pp.102-113.
Misiak, Błażej, Przemysław Bieńkowski, and Jerzy Samochowiec. "Cariprazine-a novel antipsychotic drug and its place in the treatment of Schizophrenia." Psychiatr Pol 52, no. 6 [2018]: 971-981.
McCormack, P. L. [2015]. Cariprazine: first global approval. Drugs, 75, 2035-2043.
Nasrallah, Henry A., Willie Earley, Andrew J. Cutler, Yao Wang, Kaifeng Lu, István Laszlovszky, György Németh, and Suresh Durgam. "The safety and tolerability of Cariprazine in long-term treatment of Schizophrenia: a post hoc pooled analysis." BMC psychiatry 17, no. 1 [2017]: 1-13.
Gyertyán, István, Béla Kiss, Katalin Sághy, Judit Laszy, Györgyi Szabó, Tamás Szabados, Larisza I. Gémesi et al. "Cariprazine [RGH-188], a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents." Neurochemistry international 59, no. 6 [2011]: 925-935.
Veselinović, Tanja, Michael Paulzen, and Gerhard Gründer. "Cariprazine, a new, orally active dopamine D2/3 receptor partial agonist for the treatment of Schizophrenia, bipolar mania and depression." Expert Review of Neurotherapeutics 13, no. 11 [2013]: 1141-1159.
Fagiolini, Andrea, José Ángel Alcalá, Thomas Aubel, Wojciech Bienkiewicz, Mats Magnus Knut Bogren, Joaquim Gago, Giancarlo Cerveri et al. "Treating Schizophrenia with Cariprazine: from clinical research to clinical practice. Real world experiences and recommendations from an International Panel." Annals of General Psychiatry 19, no. 1 [2020]: 1-11.
Saraf, Gayatri, Jairo Vinícius Pinto, and Lakshmi N. Yatham. "Efficacy and safety of Cariprazine in the treatment of bipolar disorder." Expert Opinion on Pharmacotherapy 20, no. 17 [2019]: 2063-2072.
Shrivastava, alankar, radhika aggarwal, rishi pratap singh, and rakhi khabiya. "a mini review on properties, mechanism of action, pharmacokinetic and pharmacodynamics and analytical methods of cariprazine." Int j app pharm 15, no. 1 [2023]: 31-35.
Hope J, Keks NA. Cariprazine: A new partial dopamine agonist with a familiar profile. Australasian Psychiatry. 2022 Jun;30[3]:382-5.
Mucci, F., Della Vecchia, A., Baroni, S. and Marazziti, D., 2021. Cariprazine as a therapeutic option for Schizophrenia: a drug evaluation. Expert Opinion on Pharmacotherapy, 22[4], pp.415-426.
Ragguett, Renee-Marie, and Roger S. McIntyre. "Cariprazine for the treatment of bipolar depression: a review." Expert Review of Neurotherapeutics 19, no. 4 [2019]: 317-323.
Ramsay C. Cariprazine pharmacokinetics. Australian Prescriber. 2022 Feb 1;45[1]:9-.